|
Status |
Public on Apr 21, 2017 |
Title |
post17 |
Sample type |
SRA |
|
|
Source name |
AA patient_post-treatment
|
Organism |
Homo sapiens |
Characteristics |
subject status: patients with Alopecia Areata time point: at 8 weeks of treatment with Tofacitinib Citrate 5 mg BID tissue: scalp biopsy
|
Extracted molecule |
total RNA |
Extraction protocol |
poly-A pull-down library preparation using Illumina TruSeq RNA prep kit
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 2000 |
|
|
Data processing |
alignment was performed to mouse genome build NCBI/build37.2 using Tophat. Differential expression analysis for RNASeq was performed using DESeq. Genome_build: NCBI/build37.2 Supplementary_files_format_and_content: RNASeq normalized counts, text file
|
|
|
Submission date |
Apr 26, 2016 |
Last update date |
May 15, 2019 |
Contact name |
Anthony Oro |
E-mail(s) |
oro@stanford.edu
|
Organization name |
Stanford University
|
Department |
Dermatology
|
Lab |
Oro
|
Street address |
269 Campus Drive, CCSR 2145c
|
City |
Stanford |
State/province |
CA |
ZIP/Postal code |
94305 |
Country |
USA |
|
|
Platform ID |
GPL11154 |
Series (1) |
GSE80688 |
Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate for Alopecia Areata and Variants |
|
Relations |
BioSample |
SAMN04903213 |
SRA |
SRX1728047 |